Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created…
AGC Biologics Seattle Facility Celebrates Milestone Year with Regulatory Approvals, Quality Achievements, and Leadership Expansion AGC Biologics, a leading global contract development and manufacturing organization (CDMO), has announced that its Seattle, Washington facility has achieved a series of remarkable milestones…
Modeyso™ (Dordaviprone) Gains Inclusion in NCCN Clinical Practice Guidelines, Marking a Milestone in the Treatment of H3 K27M-Mutant Diffuse Glioma Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced a pivotal development for its oncology portfolio with the inclusion of Modeyso™ (dordaviprone) in…
Royalty Pharma and Deloitte Release Landmark Study on the Role of Royalties in Funding Biopharma Innovation Royalty Pharma plc (Nasdaq: RPRX), the world’s largest acquirer of biopharmaceutical royalties and a key investor in life sciences innovation, has announced the publication…
Novartis to Acquire Tourmaline Bio, Advancing Cardiovascular Pipeline with Pacibekitug for ASCVD Novartis today revealed a major step forward in its cardiovascular disease (CVD) strategy with the announcement that it has entered into an agreement to acquire Tourmaline Bio, Inc.…
Avanzanite Bioscience Strengthens Leadership with Appointment of Dr. Mark Bechter as Senior Vice President of Medical Affairs Avanzanite Bioscience B.V., a rapidly expanding European specialty pharmaceutical company dedicated to improving the lives of patients with rare diseases, announced today the…
Alnylam Pharmaceuticals Prices Upsized $575 Million Convertible Senior Notes Offering, Strengthening Balance Sheet and Advancing Growth Strategy Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a recognized global leader in RNA interference (RNAi) therapeutics, has announced the successful pricing of its private offering…
France Grants Reimbursed Compassionate Access for Agenus’ Botensilimab plus Balstilimab in Refractory MSS Metastatic Colorectal Cancer In a significant development for patients with advanced colorectal cancer, Agenus Inc. (Nasdaq: AGEN), a biotechnology company at the forefront of immuno-oncology innovation, announced…
RION Launches INTENT Biologics to Advance Late-Stage Clinical Exosome Therapies in Inflammation & Immunology; Appoints Industry Leader Suneet Varma as CEO RION, a clinical-stage regenerative medicine company recognized globally for its pioneering work in exosome-based therapeutics, has announced the formation…
Evonik and Ethris Forge Strategic Alliance to Redefine Nucleic Acid Delivery with Novel Lipid Nanoparticle Platform In a move that underscores the rapid evolution of nucleic acid-based medicines and the growing importance of advanced drug delivery technologies, Evonik, a global…
Alnylam Pharmaceuticals Launches $500 Million Convertible Senior Notes Offering to Strengthen Strategic Flexibility and Advance RNAi Pipeline Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the biotechnology pioneer recognized worldwide as the leader in RNA interference (RNAi) therapeutics, has announced the commencement of…
Tolerance Bio and ZipCode Bio Forge Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics In a landmark move that underscores the growing intersection of immunology and RNA-based medicine, Tolerance Bio, a young biopharmaceutical company dedicated to extending healthspan by preserving…